BiotechTube
ProBioGen

ProBioGen

Berlin, Germany· Est.
probiogen.de
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $15M

Overview

ProBioGen AG is a Berlin-based, privately held CDMO and technology provider founded in 1994, serving the biologics and advanced therapy sectors. The company operates a dual business model, offering comprehensive contract services (cell line development, process development, GMP manufacturing) alongside a suite of proprietary technology platforms for both protein and viral vector production. With a focus on 'German Quality,' ProBioGen supports clients from preclinical stages through clinical manufacturing, targeting a growing market for outsourced biologics and viral vector production. Its financial position is likely stable as a revenue-generating service provider, though specific figures are not disclosed.

BiologicsCell Therapy

Technology Platform

Proprietary platforms for protein/antibody production (CHO.RiGHT®, GlymaxX®, DirectedLuck®) and viral vector/vaccine production (AGE1.CR.pIX®, MVA-CR19, Lenti.RiGHT®, DirectedLuck®).

Funding History

2
Total raised:$15M
Grant$5M
Series A$10M

Opportunities

Strong growth in outsourcing for complex biologics and viral vectors, driven by the expanding cell/gene therapy market.
Proprietary technology platforms provide differentiation and allow for premium services.
Strategic location in Europe's biopharma hub facilitates access to a global client base.

Risk Factors

Intense competition from larger, global CDMOs.
Dependence on client project success and potential for concentration risk.
High capital requirements and execution risks associated with scaling GMP manufacturing capacity, especially for viral vectors.

Competitive Landscape

Operates in a crowded CDMO market competing against large players (e.g., Lonza, Catalent) and specialized firms. Differentiation is achieved through integrated proprietary technology platforms for both proteins and viral vectors, a niche not all CDMOs possess. The focus on 'German quality' and scientific expertise targets clients seeking high-touch, innovative partners.

More companies in Biologics / Biosimilars →More companies in Germany →